Lactobacillus reuteri
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02124122 | Mar → Nov 2015 | — | Tulane University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00774163 | Feb → Jun 2010 | — | Tulane University School of Medicine | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07370519 | Jan 2026 → Jan 2027 expected | androgenetic alopecia | Shenzhen People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06285591 | Mar 2024 → Jan 2025 | head and neck cancer | West China Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03552458 | Jun 2018 → Dec 2020 | head and neck cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 34 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT05852990 | Mar 2022 → Dec 2026 expected | non-small cell lung carcinoma | National Cancer Institute of Mexico | Recruiting | No outcome recorded |
| Phase 3 | NCT04209777 | Jul 2018 → Apr 2019 | chronic periodontitis | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01531179 | Feb 2012 → Feb 2013 | necrotizing enterocolitis | Zekai Tahir Burak Women's Health Research and Education Hospital | Completed | Missed primary |
| Phase 3 | NCT01870700 | Jan → Jun 2012 | constipation disorder | Catholic University, Italy | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT06834815 | Nov 2024 → Feb 2025 | — | Ain Shams University | Completed | No outcome recorded |
| Phase not applicable6 trials · 1 missed | ||||||
| — | NCT07512050 | Apr → Jun 2026 overdue | — | Shenzhen People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05710575 | Feb → Jun 2023 | perinatal necrotizing enterocolitis | University of Health Sciences Lahore | Completed | No outcome recorded |
| — | NCT03692819 | May 2018 → Aug 2020 | chronic periodontitis | São Paulo State University | Completed | No outcome recorded |
| — | NCT03019172 | Mar → Jul 2017 | urinary tract infection | Innovacion y Desarrollo de Estrategias en Salud | Completed | No outcome recorded |
| — | NCT03030664 | Mar 2017 → Jun 2021 | constipation disorder | Centre Hospitalier Intercommunal Creteil | Completed | Missed primary |
| — | NCT01743690 | Mar 2012 → Dec 2015 | candidiasis, lichen planus, oral | University of Copenhagen | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01849991 Comparator | Sep 2013 → Apr 2016 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1 | NCT00922727 Comparator | Oct 2009 → Jul 2011 | digestive system infectious disorder | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| — | NCT02693028 Comparator | Nov 2015 → Jan 2018 | pregnancy disorder | Sahlgrenska University Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Winclove Probiotics B.V. | Results Stress and resilience: gut insights for World Mental Health Day wincloveprobiotics.com ↗
Mice supplemented with L. reuteri showed increased stress hormone levels in the bright phases of day, while the stress hormones during the night remained unchanged. |
| 2024-11-25 | AB Biotics, SA | Results WCPGHAN 2024: Discover the compelling results of the first comparative clinical trial between AB-KOLICARE® and L. reuteri DSM17938 for infant colic ab-biotics.com ↗
Moreover, the response rates for both probiotic groups aligned with previously published results, reinforcing the reliability of the data. |
| 2021-05-12 | Genome & Company | Results [보도자료] 지놈앤컴퍼니 자회사 사이오토 바이오사이언스 ‘ABT플랫폼™’효과, 의학전문지 ‘뇌∙행동∙면역’에 게재 genomecom.co.kr ↗
동물 모델 실험 결과 , 기존의 L. Reuteri 단독 균주보다 ABT 플랫폼 기술에 해당 균주를 접목했을 때 , NEC 발병율 감소 , 인지기능 장애 예방 , 불안행동 감소 등에서 더 나은 효능을 확인했다 . |
| 2017-08-31 | Scioto Biosciences, Inc. | Results Enhanced Probiotic Potential of Lactobacillus reuteri When Delivered as a Biofilm on Dextranomer Microspheres That Contain Beneficial Cargo sciotobiosciences.com ↗
These data support the continued development of this novel probiotic formulation as an adaptable and effective means for targeted delivery of cargo beneficial to the probiotic bacterium. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Winclove Probiotics B.V. | Stress and resilience: gut insights for World Mental Health Day wincloveprobiotics.com ↗ |
| 2024-11-25 | AB Biotics, SA | WCPGHAN 2024: Discover the compelling results of the first comparative clinical trial between AB-KOLICARE® and L. reuteri DSM17938 for infant colic ab-biotics.com ↗ |
| 2021-05-12 | Genome & Company | [보도자료] 지놈앤컴퍼니 자회사 사이오토 바이오사이언스 ‘ABT플랫폼™’효과, 의학전문지 ‘뇌∙행동∙면역’에 게재 genomecom.co.kr ↗ |
| 2017-08-31 | Scioto Biosciences, Inc. | Enhanced Probiotic Potential of Lactobacillus reuteri When Delivered as a Biofilm on Dextranomer Microspheres That Contain Beneficial Cargo sciotobiosciences.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus-reuteri | “This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients...” NCT05852990 ↗14“The aim of this randomised clinical trial was to evaluate the effect of Lactobacillus reuteri in chewable tablets as an adjunct to non-surgical periodontal treatment of chronic...” PMID 30931588 ↗ Apr 2019 “Lactobacillus-reuteri probiotics were used as an experimental drug.” NCT04209777 ↗ “probiotics (Streptococcus salivarius M18 and Lactobacillus reuteri)” NCT06834815 ↗ “Lactobacillus Reuteri (probiotic bacteria) given to pregnant women” NCT02693028 ↗ |
| Known as | BioGaia | “The active agent; Lactobacillus reuteri Prodentis (Biogaia ®) will be supplied in droplet form by Pharma forte Singapore Pte Ltd and dosage used will be as recommended by...” NCT03552458 ↗ |
| Known as | DSM 17938 | “Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici,...” NCT01870700 ↗4“Infants in the first group were given 100 million CFU/day (5 drops) of lyophilised L reuteri (DSM 17938) mixed in breast milk or formula, starting from first feeding until discharge.” PMID 24309022 ↗ Dec 2013 “L reuteri strain DSM 17938 produced no severe adverse events and did not significantly change crying time, plasma bicarbonate, or inflammatory biomarkers.” PMID 28969890 ↗ Sep 2017 “This is a Phase 1 study to assess the safety and tolerability of Lactobacillus reuteri (Lr) strain DSM 17938 in healthy children in Peru.” NCT02124122 ↗ “oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden)” NCT05710575 ↗ |
| Known as | L. reuteri | “The aim of the present study was to assess and compare the clinical efficacy of local probiotic Lactobacillus reuteri (L. reuteri) and systemic antibiotics as adjunct to...” PMID 30663271 ↗ Jan 20197“The placebo lozenges shared the same formulation as the L. reuteri lozenges but without the probiotic, whose appearance, taste, and color were identical to those of the...” NCT06285591 ↗ “Infants in the first group were given 100 million CFU/day (5 drops) of lyophilised L reuteri (DSM 17938) mixed in breast milk or formula, starting from first feeding until discharge.” PMID 24309022 ↗ Dec 2013 “L reuteri strain DSM 17938 produced no severe adverse events and did not significantly change crying time, plasma bicarbonate, or inflammatory biomarkers.” PMID 28969890 ↗ Sep 2017 “oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden)” NCT05710575 ↗ “The lozenges containseither two strains of the probiotic bacterium L. reuteri (A) or placebo (B).” NCT01743690 ↗ |
| Known as | Lactobacillus reuteri DSM 17938 | “The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938.” NCT00922727 ↗ |
| Known as | Lactobacillus reuteri Prodentis | “The active agent; Lactobacillus reuteri Prodentis (Biogaia ®) will be supplied in droplet form by Pharma forte Singapore Pte Ltd and dosage used will be as recommended by...” NCT03552458 ↗ |
| Known as | Limosilactobacillus reuteri | “Limosilactobacillus reuteri (LR) probiotic to prevent and reduce the severity of OM in head and neck cancer patients undergoing radiotherapy (RT).” PMID 40887814 ↗ Aug 20251“Preliminary studies suggest that the probiotic Limosilactobacillus reuteri (L. reuteri) may be useful in treating constipation in children” PMID 36389355 ↗ Oct 2022 |
| Action | Inhibit | “reduce the growth of candida albicans in vitro” NCT01743690 ↗ |
| Modality | Other / unclassified | “Lactobacillus reuteri oil drops are a natural product” NCT00922727 ↗ |
| Route | Oral | “The patients will receive 5 drops (10\^8 live organisms) by mouth daily for 60 days.” NCT00922727 ↗ |